| Name | Title | Contact Details |
|---|
Since 1965, Telecare has been committed to making a difference in the lives of people with serious mental illness. We believe in Recovery, and in the human ability and desire to reach its full potential. We have created an environment that puts the
Copper Queen Community Hospital has a rich heritage, dating back to the 1880s when it operated as a part of the mining community, so important to the history of Bisbee.
In July 2014, Genoa Healthcare and QoL meds combined to create Genoa, a QoL Healthcare Company, the nation`s leading behavioral health specialty pharmacy company. This merger brought together two pharmacy organizations with proven track records for excellent service to individuals with mental illness. Both companies had strong reputations for outstanding customer service, flexibility and delivering true value to their consumers and partners. By uniting their strengths – like best practices and expertise – the combined company was able to better serve individuals and the health organizations that care for them over the past year. Genoa has been serving the behavioral health community for over 15 years. The company now provides specialty behavioral health and long-term care pharmacy services to more than 500,000 individuals annually, operating over 285 pharmacies in 39 states and the District of Columbia and filling more than 9 million prescriptions per year. Although Genoa specializes in serving behavioral health consumers, we are a full-service pharmacy. This means we take care of all the medication needs of our consumers, including prescriptions written by psychiatrists, primary care providers, or other specialty prescribers. Genoa remains flexible to the many behavioral health and primary care delivery models across the country and developed services within our pharmacies to meet the needs of those specific models. None of our service models or pharmacies are the same. We take pride in not being a "cookie cutter" organization, and continue to seek opportunities nationwide to help behavioral health communities with their pharmacy services.
We are on the leading edge of research, development, clinical trials, and implementation of digital solutions that are aimed at harm reduction for various public health challenges. Our goal is to reduce harm and prevent unintentional deaths for people of all ages. Our team has pioneered apps that were developed in response to the opioid crisis, which is now a world-wide problem, as well as the COVID-19 pandemic and health & safety concerns in senior care centers.
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.